Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Products under Development by Stage of Development | 8 | 1 |
| Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Products under Development by Therapy Area | 9 | 1 |
| Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Products under Development by Indication | 10 | 1 |
| Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Products under Development by Companies | 13 | 2 |
| Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Products under Development by Universities/Institutes | 15 | 2 |
| Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Companies Involved in Therapeutics Development | 23 | 4 |
| Cantex Pharmaceuticals, Inc. | 23 | 1 |
| Chiesi Farmaceutici SpA | 24 | 1 |
| Kamada Ltd. | 25 | 1 |
| Polyphor Ltd. | 26 | 1 |
| Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Drug Profiles | 27 | 15 |
| alpha-1 proteinase inhibitor (human) Drug Profile | 27 | 5 |
| ANV-201 Drug Profile | 32 | 1 |
| Brevenal Drug Profile | 33 | 1 |
| CX-01 Drug Profile | 34 | 2 |
| POL-6014 Drug Profile | 36 | 2 |
| Polysaccharides to Inhibit P-Selectin and HLE for Age-Related Macular Degeneration Drug Profile | 38 | 1 |
| Small Molecule 1 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders Drug Profile | 39 | 1 |
| Small Molecule 2 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders Drug Profile | 40 | 1 |
| Small Molecules to Inhibit Neutrophil Elastase for Respiratory Diseases Drug Profile | 41 | 1 |
| Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Dormant Projects | 42 | 3 |
| Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Discontinued Products | 45 | 1 |
| Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Featured News &Press Releases | 46 | 15 |
| Jun 15, 2016: Shire and Kamada announce FDA approval of expanded label for self-infusion of Glassia for the treatment of emphysema due to severe AAT deficiency | 46 | 1 |
| May 25, 2016: Kamadas Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early Access Platform | 47 | 1 |
| Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection | 47 | 2 |
| Mar 28, 2016: Kamada Submits Marketing Authorization Application with the European Medicines Agency for its Proprietary Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency | 49 | 2 |
| Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia | 51 | 1 |
| Jan 06, 2016: Kamada Reports Further Positive Interim Data from Phase 1/2 Study of its Alpha-1 Antitrypsin to Treat Graft Versus Host Disease | 51 | 1 |
| Dec 02, 2015: Kamada Provides Update on Alpha-1 Antitrypsin Development in Newly Diagnosed Type 1 Diabetes | 52 | 1 |
| Sep 01, 2015: Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I | 53 | 1 |
| Jul 06, 2015: Kamada Announces Publication in Pediatric Diabetes | 54 | 1 |
| Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection | 55 | 1 |
| Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01 | 56 | 1 |
| May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting | 56 | 1 |
| May 06, 2015: Kamada to Present Key Results from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin During the American Thoracic Society 2015 International Conference | 57 | 1 |
| Apr 01, 2015: Kamada Receives Allowance for Key Canadian Patent for Large Scale Production and Use of Proprietary Alpha-1 Proteinase Inhibitor | 58 | 1 |
| Mar 23, 2015: Kamada Awarded European Orphan Drug Designation for Its Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease | 59 | 2 |
| Appendix | 61 | 2 |
| Methodology | 61 | 1 |
| Coverage | 61 | 1 |
| Secondary Research | 61 | 1 |
| Primary Research | 61 | 1 |
| Expert Panel Validation | 61 | 1 |
| Contact Us | 61 | 1 |
| Disclaimer | 62 | 1 |